CDKN2A and breast neoplasm: These differences coincide with high p16 (CDKN2A) (χ2 test; P = 0.0007), and low pRb (RB1) in the triple-negative subtype of BRCA2 mutated breast tumors (χ2 test; P = 0.085) (Table 1).